MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$153,531K
(-21.05%↓ Y/Y)
Net loss
-$153,494K
(-20.98%↓ Y/Y)
Unrealized income (loss) on
investments
-$37K
(-184.09%↓ Y/Y)
Jelmyto
$93,989K
Zusduri
$15,799K
Loss before income
taxes
-$153,416K
(-23.68%↓ Y/Y)
Income tax expense
$78K
(-97.25%↓ Y/Y)
Interest and other
income, net
$5,295K
(-38.94%↓ Y/Y)
Revenue
$109,788K
(21.45%↑ Y/Y)
Operating loss
-$124,863K
(-29.01%↓ Y/Y)
Financing on prepaid
forward obligation
$18,503K
(-20.96%↓ Y/Y)
Interest expense on
long-term debt
$15,345K
(22.55%↑ Y/Y)
Gross profit
$97,341K
(19.41%↑ Y/Y)
Cost of revenue
$12,447K
(40.15%↑ Y/Y)
Selling, general and
administrative expenses
$155,097K
(28.02%↑ Y/Y)
Research and development
expenses
$67,107K
(17.43%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)